12
Feb
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The acute migraine drug market size...
Press Release
test
04
Feb
PALO ALTO, February 4, 2023 /Newswire/ -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused...
02
Feb
Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the
29
Jan
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
PALO ALTO, January 29, 2023 (GLOBE NEWSWIRE)...
10
Nov
Approximately 80% of the shareholders of Vickers present at the meeting of Vickers shareholders in connection with the business combination voted in favor of the business combination. Scliex’s shares of common stock and...
10
Nov
Scilex Holding Company to Ring the Nasdaq Opening Bell on Friday November 11, 2022 at 9:30 a.m. ET
Scilex plans to accelerate growth as a public company and advance...
31
Oct
SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9,...
29
Sep
Pre-emptive pay off of the Senior Secured Notes (the “Notes”) eliminated the prior $28.0 million increase in the principal amount of the Notes
PALO ALTO and SAN DIEGO, CA....
30
Aug
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following:More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure...
17
Aug
PALO ALTO, CA. August 17, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced...
